Celsion OK'd for China Phase III Trial of Liver Cancer Treatment

Celsion of New Jersey received CFDA approval to conduct China clinical trials of its liver cancer drug, ThermoDox®, as part of a Phase III global study. ThermoDox is Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin. In 2013, ThermoDox failed a Phase III trial when it didn't increase survival, but a retrospective analysis suggested longer heat-activation treatment would improve results. Zhejiang Hisun Pharma (SHA: 600267) of China has first rights to bid on marketing the drug in China. More details.... Stock Symbol: (NSDQ: CLSN) Share this with colleagues: // //